INSERM, U785, Centre Hépatobiliaire, Villejuif F-94800, France.
J Hepatol. 2013 Feb;58(2):385-7. doi: 10.1016/j.jhep.2012.08.019. Epub 2012 Aug 30.
Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma(HCC), a long-term consequence of chronic liver injury, inflammation,and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota and TLR4 activation in nonbone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
肠道细菌易位增加是慢性肝病的一个标志,并导致肝炎症和纤维化。在这里,我们测试了这样一个假设,即肠道微生物群和 Toll 样受体 (TLRs) 促进肝癌 (HCC),这是慢性肝损伤、炎症和纤维化的长期后果。慢性损伤肝脏中的肝癌发生依赖于肠道微生物群和非骨髓来源的驻留肝细胞中的 TLR4 激活。TLR4 和肠道微生物群不是 HCC 起始所必需的,但对于 HCC 的促进是必需的,介导了增殖增加、促肝细胞分裂原 epiregulin 的表达和阻止细胞凋亡。仅限于肝癌发生后期的肠道消毒可减少 HCC,表明肠道微生物群和 TLR4 是晚期肝病中 HCC 预防的治疗靶点。